Adverse events according to treatment regimen in the RITAZAREM trial
| Total (N=188) | Rituximab (N=85) | Azathioprine (N=85) | Not randomised (N=18) | |
| Number (%) of patients with a serious adverse event | 92 (49%) | 37 (44%) | 48 (56%) | 7 (39%) |
| Number (%) of patients with a serious infection | 39 (21%) | 15 (18%) | 19 (22%) | 5 (28%) |
| Number (%) of patients with a non-serious infection | 119 (63%) | 54 (64%) | 62 (73%) | 3 (17%) |
| Number (%) of patients with plasma IgG<5 g/L | 66 (35%) | 36 (42%) | 26 (31%) | 4 (22%) |
| Number (%) of patients with plasma IgG<3 g/L | 17 (9%) | 8 (9%) | 6 (7%) | 3 (17%) |